ADVISORY, April 21, 2008 (PRIME NEWSWIRE) --
Who: Dr. Solomon Steiner, Chief Executive Officer and Chairman of Biodel, Inc. (BIOD), will preside over the Closing Bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Tuesday, April 22 at 4:00 p.m. EDT Contacts: Rebecca Der 212.213.0006 rder@burnsmc.com NASDAQ MarketSite: Robert Madden 646.441.5045 Robert.Madden@NASDAQOMX.com
Feed Information:
The Closing Bell is available from 3:50 p.m. to 4:05 p.m. on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Robert Madden at (646) 441-5045.
Radio Feed:
An audio transmission of the Closing Bell is also available from 3:50 p.m. to 4:05 p.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Waterfront fiber 1623 as well.
Webcast:
A live Webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Biodel, Inc. (BIOD):
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(tm) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(tm), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(tm) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(tm), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at www.biodel.com.